You Position: Home > Paper
Effects of neoadjuvant radiochemotherapy on pathological stage and prognosis of middle and advanced esophageal carcinoma
( views:267, downloads:9 )
- Author:
- No author available
- Journal Title:
- WORLD CHINESE JOURNAL OF DIGESTOLOGY
- Issue:
- 22
- DOI:
- 10.3969/j.issn.1009-3079.2007.22.009
- Key Word:
- 食管肿瘤;新辅助放化疗;病理分期;预后
Abstract： 目的:评估新辅助放化疗对中晚期食管鳞癌病理分期及预后的影响.方法:1991-01/2000-12中晚期食管鳞癌患者473例,随机分为4组,新辅助放疗组(n=118)、新辅助化疗组(n=119)、新辅助放化疗组(n=118)及对照组(单纯手术)(n=118).统计分析4组在切除率、病理分期、并发症、生存期等方面的差别.结果:放疗组、化疗组、放化组与对照组相比均可提高根治性切除率(97.5%,86.6%,98.3% vs 73.7%,均(P＜0.01);放疗组、放化组与对照组相比有明显降期作用(P＜0.01);而化疗组没有明显降期作用.放疗组、化疗组、放化组与对照组相比,手术并发症无明显增加(P＞0.05),放疗组、放化组的3 a生存率相比对照组显著提高(69.5%,73.7% vs 53.4%,均P＜0.01).放化组的5 a生存率优于放疗组,但无统计学意义(45.0% vs 40.7%,P＞0.05).结论:合理应用新辅助放化疗可提高中晚期食管鳞癌患者生存期并提高其生存质量.
- [1]Frédéric Di Fiore,Stéphane Lecleire,Olivier Rigal,etc.Predictive factors of survival in patients treated with definitive chemoradiotherapy for squamous cell esophageal carcinoma[J].2006,(26).
- [2]Fumiko Sunada,Masayuki Itabashi,Hisanao Ohkura,etc.p53 negativity, CDC25B positivity, and metallothionein negativity are predictors of a response of esophageal squamous cell carcinoma to chemoradiotherapy[J].2005,(36).
- [3]张超南,曹秀峰,袁爱华,等.新辅助放化疗对中晚期食管癌切除率和预后的影响[J].2003,(6).
- [4]曹秀峰,王和明,吴必超,等.选择性术前放化疗对食管癌切除率的影响[J].2004,(1).
- [5]陈克能,徐光炜.食管癌的诊断和治疗[J].2000,(2).
- [6]Mariette C,Triboulet JP.Oesophageal squamous cell carcinoma stade III. State of surgery after radiochemotherapy (RCT)[J].2006,10(6).
- [7]柴树德,郑广钧.放射性粒子植入治疗胸部肿瘤[M].2007.
- [8]S, Msika,J M, Hay.[Value of radiotherapy and chemotherapy in treatment of operable cancers of the esophagus].[J].2002,139(1).
- [9]Sasaki Y,Ohigashi H,Yokoyama S,etc.Cytokeratin deposits in lymph nodes show distinct clinical significance from lymph node micrometastasis in human esophageal cancers.[J].2002,107(1).
- [10]Stein HJ,Siewert JR.Improved prognosis of resected esophageal cancer.[J].2004,28(6).
- [11]J, Rous,B, Simecková,V, Fencl.[Late organic and functional findings in children following tracheotomy].[J].1976,25(2).
- [12]I, Popescu,M, Ionescu,S, Ciurea,etc.[Neoadjuvant radiochemotherapy in the treatment of esophageal squamous carcinoma: Preliminary results in a series of 15 patients].[J].1900,98(6).
- [13]O'Reilly E,Levnor A,Schwartz GK,etc.Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma.[J].2006,24(33).
- [14]S E, Baldus,S P, M?nig,W, Schr?der,etc.[Regression of oesophageal carcinomas after neoadjuvant radiochemotherapy: criteria of the histopathological evaluation].[J].2004,25(6).
- [15]Christiansen H,Haller F,Hille A,etc.Histomorphological tumor regression grading of esophageal carcinoma after neoadjuvant radiochemotherapy: which score to use?[J].2006,19(5).
- [16]Sarbia M,Brucher BL,Busch R,etc.Responders benefit from neoadjuvant radiochemotherapy in esophageal squamous cell carcinoma: results of a prospective phase-II trial.[J].2004,30(9).
- [17]A, Del Genio.[Laparoscopic esophagectomy in palliative treatment of advanced esophageal carcinoma after neoadjuvant radiochemotherapy].[J].2005,26(4).
- [18]Fernando, Delgado Gomis,Segundo A, Gómez Abril,Manuel, Martínez Abad,etc.Assisted laparoscopic transhiatal esophagectomy for the treatment of esophageal cancer.[J].2006,8(3).